Citations

Showing 10 of 108152 citations.

Surgical management of a giant congenital left ventricular aneurysm in a 2‐month‐old infant
Egunov, O.A. , Кривощеков, Е. В. , Cetta, Frank , Aa, Sokolov , Sviazov, Evgenii A. , Egunov, Oleg A , Krivoshchekov, Evgeny V , Sokolov, Alexander A

Mayo Clinic

Journal of Cardiac Surgery | May 6, 2021 | Volume: 36 | Issue: 7 | Pages: 2575-2577

10.1111/jocs.15566 | PMID 33955054 Get It

Integrated Retinal Amyloid Burden With Retinal Venular Tortuosity Predicts Verbal Memory Impairment
Dumitrascu, Oana M. , Rosenberry, Ryan , Sherman, Dale , Khansari, Maziyar M. , Sheyn, Julia, Torbati, Tania , Sherzai, Ayesha , Johnson, Kenneth O., Czeszynski, Alan , Verdooner, Steven, Black, Keith L. , Lyden, Patrick D. , Fan, Zhaoyang , Koronyo, Yosef, Sherzai, Dean , Johnson, Kenneth O., Frautschy, Sally A. , Shi, Yonggang , Cheng, Susan , Koronyo‐Hamaoui, Maya , Black, Keith L

Mayo Clinic

No container title available | May 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-481178/v1 Get It

Abstract INTRODUCTION: Retinal imaging is a non-invasive tool to study retinal vasculature and neurodegeneration. Patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD)-related cognitive disorder exhibit both retinal vascular abnormalities and intraretinal accumulation of amyloid beta-protein (Aβ) plaque. Curcumin-enhanced retinal fluorescence imaging (CRFI) was recently translated as a safe imaging tool for retinal Aβ plaque quantification, holding promise as an early-stage pathological biomarker of AD. In this exploratory study, we sought to determine whether retinal vascular features combined with retinal amyloid burden correlate with the neurocognitive status.METHODS: We used scanning laser ophthalmoscopy to assess quantitative CRFI in a cohort of patients with cognitive impairment that underwent standard neuropsychological testing. Retinal blood vessels were segmented in a predefined circumpapillary region of interest. For each centerline, vessel tortuosity index, vessel inflection index and branching angle was quantified. Additionally, we automatically quantified retinal amyloid count in the supero-temporal quadrant and its subregions: posterior pole, proximal mid-periphery, and distal mid-periphery. Investigators performing quantifications were blinded to the subjects’ clinical characteristics. Linear regression models were used to assess the correlations between retinal vascular and amyloid parameters and cognitive domain Z-scores.RESULTS: In this pilot study, 34 subjects underwent automated retinal amyloid imaging and 29 subjects (55% female, mean age 64±6 years) had the combined retinal amyloid and peripapillary vascular analysis. Eleven subjects had normal cognition, 15 MCI, 2 probable AD and 1 non-AD dementia. CRFI was increased in individuals with impaired versus normal cognitive function (p 0.0012). Venous VTI was the most significant vascular parameter that differ across levels of CDR. Branching angle correlated with amyloid count in the distal mid-periphery (p=0.03), whereas vessel inflexion index correlated with posterior pole amyloid count (p=0.02). The combined proximal mid-periphery amyloid count – venous tortuosity index was found to exhibit highly significant group differences between cognitively impaired and cognitively normal subjects (0.49 ± 1.1 vs 0.91 ± 1.4, p=0.006). The combined proximal mid-periphery amyloid-venous tortuosity index also correlated with verbal memory (Wechsler Memory Scale-IV; p=0.001) and cognitive-related quality of life (SF-36 mental component score Z-scores; p=0.039).CONCLUSION: Retinal venular tortuosity discriminates across cognitive scores and in combination with proximal mid-periphery amyloid count predicts verbal memory and cognitive-related quality-of-life. Future research is needed to confirm the clinical utility of this integrated retinal imaging-based methodology.
Assessment of Gender Parity: Leadership Representation in Pulmonary and Critical Care Medicine
Olson, Emily M. , Kennedy, Cassie C. , Kelm, Diana J. , Kennedy, Cassie C

Mayo Clinic

Journal of Women's Health | May 6, 2021 | Volume: 31 | Issue: 3 | Pages: 439-446

10.1089/jwh.2020.8982 | PMID 33956512 Get It

Background: Academic centers' and professional societies' top leadership representation and professional societies' award recipients remain disparate by gender in many fields. Little is known regarding leadership representation and recognition within pulmonary, critical care, and sleep medicine (PCCM), which has ∼22% women physicians. We sought to understand the landscape of female PCCM leaders. Methods: We abstracted gender of fellowship program directors (PDs), Department of Medicine (DOM) Chairs and Division Chiefs from academic medical centers with PCCM fellowship programs from 2018 and for comparison 2008. We abstracted leadership and recognition award recipients within four PCCM professional societies from 2013 to 2018 (American Thoracic Society [ATS], American Academy of Sleep Medicine [AASM], American College of Chest Physicians [CHEST], and Society of Critical Care Medicine [SCCM]). Results: In 2018, 29% of PCCM PD, 15% of PCCM Division Chiefs, and 15% of DOM Chairs were women. There were significantly more female PDs in 2018 (29%) compared with 2008 (16%, p = 0.04). On average, 25% of society presidents were women, with 28% of PCCM societal awards going to women, with significant difference between societies ( p = 0.04). Each society differed in average distribution of female board members over the 6-year period: ATS 38%, AASM 35%, CHEST 18%, and SCCM 44% ( p < 0.001). Conclusion: PCCM leadership and societal recognition are disparate by gender with few women holding top leadership roles and receiving societal recognition. Fortunately, the distribution notably is starting to reflect the specialty's demographics. Understanding why these inequalities exist will be essential to achieving gender parity in PCCM.
Reply to Karakonstantis, et al; Zervou and Zacharioudakis; and Rasmussen, et al
Peinado-Acevedo, Juan Sebastián , Hurtado-Guerra, Juan José , Hincapié, Carolina , Mesa-Abad, Juanita, Uribe-Delgado, José Roberto , Giraldo-Ramírez, Santiago, Lengerke-Diaz, Paula A. , Diaz, Paula A Lengerke , Jaimes, Fabián

Mayo Clinic

Clinical Infectious Diseases | May 6, 2021 | Volume: 74 | Issue: 1 | Pages: 167-168

10.1093/cid/ciab423 | PMID 33972986 Get It

Self-reported physical activity before a COVID-19 ‘lockdown’: is it just a matter of opinion?
Cross, Troy J. , Isautier, Jennifer , Stamatakis, Emmanuel , Morris, Sarah J. , Johnson, Bruce D. , Wheatley, Courtney M. , Taylor, Bryan J. , Wheatley-Guy, Courtney, Cross, Troy James , Taylor, Bryan J

Mayo Clinic

BMJ Open Sport & Exercise Medicine | May 6, 2021 | Volume: 7 | Issue: 2 | Pages: e001088

10.1136/bmjsem-2021-001088 | PMID 34192013 Get It

There are growing concerns that the COVID-19 pandemic has facilitated a sedentary shift in our physical activity habits. A reduction in physical activity during the pandemic may be secondary to restrictive policies implemented at the government-level, typically those policies which limit interpersonal contact; for example, physical/social distancing. It is without question that social distancing is a necessary measure to mitigate community transmission of the novel virus; however, these policies often limit the public’s opportunities to engage in physical activity. The strictest enforcement of social distancing occurs during an authority-mandated ‘lockdown’ (also known as a ‘shelter-in-place’ or ‘stay-at-home’ order). This Viewpoint focuses on the current evidence demonstrating that physical activity declines during a COVID-19 ‘lockdown’. We highlight the point that most of the available evidence stems from investigations using non-validated, self-reported measures of physical activity and discuss the caveats therewith. This Viewpoint explores whether current evidence reflects an ‘actual’ or rather a ‘perceived’ reduction in physical activity, and raises the question of whether this distinction matters in the end.
Septal myectomy in patients with hypertrophic cardiomyopathy with lesser septal thickness—mitral valve repair is not necessary
Nguyen, Anita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | May 6, 2021 | Volume: 60 | Issue: 2 | Pages: 252-252

10.1093/ejcts/ezab226 | PMID 34254139 Get It

Impact of stent length and diameter on 10‐year mortality in the SYNTAXES trial
Hara, Hironori , Ono, Masafumi , Kawashima, Hideyuki , Kogame, Norihiro , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Davierwala, Piroze , Mohr, Friedrich W., Thuijs, Daniel J.F.M. , Head, Stuart J., Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Serruys, Patrick W , Onuma, Yoshinobu , Kappetein, A. Pieter , Serruys, Patrick W. , Investigators, for the SYNTAX Extended Survival

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 6, 2021 | Volume: 98 | Issue: 3 | Pages: No page available

10.1002/ccd.29721 | PMID 33951265 Get It

AbstractObjectivesWe investigated the impact of total stent length (TSL) and average nominal stent diameter (ASD) on 10‐year mortality after percutaneous coronary intervention (PCI) in the SYNTAXES trial.BackgroundTSL and ASD in patients treated with PCI are associated with major adverse cardiovascular events. However, the treatment effect of PCI with extensive and/or small stenting as compared with coronary artery bypass grafting (CABG) for complex coronary artery disease has not been fully evaluated.MethodsImpacts on mortality of extensive stenting defined as TSL >100 mm and small stenting as ASD <3 mm were analyzed in 893 PCI patients and were compared to 865 CABG patients.ResultsTSL as a continuous variable was significantly associated with 10‐year mortality (adjusted hazard ratio [HR], 1.05 [1.01–1.09] per 10 mm increase). PCI patients with extensive stenting had a higher 10 year mortality than CABG patients (adjusted HR, 1.97 [1.41–2.74]) or not‐ extensive stenting PCI (adjusted HR, 1.94 [1.36–2.77]). Although ASD did not have a significant association with 10 year mortality (adjusted HR, 0.97 [0.85–1.11] per 0.25 mm increase), PCI with small stents was associated with a higher 10 year mortality, compared to CABG (adjusted HR, 1.66 [1.23–2.26]) and PCI performed with large stents (adjusted HR, 1.74 [1.19–2.53]). Patients treated with not‐extensive and large stents had similar mortality rates (24.0 versus 23.8%) as those treated with CABG.ConclusionsExtensive and small stenting were associated with higher 10 year mortality, compared with CABG. When patients have to be treated with extensive or small stenting, revascularization with CABG should be preferred.
Evaluation of SrAl2O4:Eu, Dy phosphor for potential applications in thermoluminescent dosimetry
Tang, Xueyan , Ehler, E , Brost, Eric, Mathew, Damien , Tang, Xueyan

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 6, 2021 | Volume: 22 | Issue: 5 | Pages: 191-197

10.1002/acm2.13251 | PMID 33951293 Get It

AbstractPurposeTo evaluate the use of commercial‐grade strontium aluminate phosphorescent powder as a thermoluminescent (TL) dosimeter for clinical radiotherapy beams.Materials and MethodCommercially available Eu2+, Dy3+ co‐doped strontium aluminate powder (SrAl2O4:Eu, Dy) was annealed and then irradiated using 20 × 20 cm2 field size, with 6‐MV (PDD10 = 70.7) and 18‐MV (PDD10 = 79.4) photon beams and and 9‐MeV (R50 = 3.6), 15 MeV (R50 = 5.9) and 18‐MeV (R50 = 7.2) electron beams. To calibrate the relationship between the TL readings and the irradiated doses, TL glow curves were acquired for doses up to 600 cGy at all beam energies. For the percentage depth dose (PDD) measurement, the SrAl2O4:Eu, Dy powder was sandwiched by solid water phantoms, with varying thickness of solid water placed above to determine the depth. PDDs were measured at four representative depths and compared against the commissioning depth dose data for each beam energy.ResultsLinear dose response models of doses up to 200 cGy were created for all beam energies. Superlinearity was observed with doses greater than 200 cGy. The PDD measurement acquired experimentally agrees well with the commissioning data of the medical linear accelerator. Trapping parameters such as order of kinetics, activation energy and frequency factor have been obtained via TL glow curve analysis.ConclusionThe linear dose response demonstrates that SrAl2O4:Eu, Dy is a potential TLD dosimeter for both electron beams and photon beams at different beam energies. The PDD measurements further support its potential use in quality assurance and radiation dosimetry.
Cyclin D2 Overexpression Enhances the Efficacy of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes for Myocardial Repair in a Swine Model of Myocardial Infarction
Zhao, Meng , Nakada, Yuji , Wei, Yuhua , Bian, Weihua , Chu, Yuxin , Borovjagin, Anton V. , Xie, Min , Zhu, Wuqiang , Nguyen, Thanh , Zhou, Yang , Walcott, Gregory P. , Zhang, Jianyi , Zhu, Wuqiang , Serpooshan, Vahid

Mayo Clinic

Circulation | May 6, 2021 | Volume: 144 | Issue: 3 | Pages: 210-228

10.1161/circulationaha.120.049497 | PMID 33951921 Get It

Background: Human induced pluripotent stem cells with normal (wild-type) or upregulated (overexpressed) levels of CCND2 (cyclin D2) expression were differentiated into cardiomyocytes (CCND2 WT CMs or CCND2 OE CMs, respectively) and injected into infarcted pig hearts. Methods: Acute myocardial infarction was induced by a 60-minute occlusion of the left anterior descending coronary artery. Immediately after reperfusion, CCND2 WT CMs or CCND2 OE CMs (3×10 7 cells each) or an equivalent volume of the delivery vehicle was injected around the infarct border zone area. Results: The number of the engrafted CCND2 OE CMs exceeded that of the engrafted CCND2 WT CMs from 6- to 8-fold, rising from 1 week to 4 weeks after implantation. In contrast to the treatment with the CCND2 WT CMs or the delivery vehicle, the administration of CCND2 OE CM was associated with significantly improved left ventricular function, as revealed by magnetic resonance imaging. This correlated with reduction of infarct size, fibrosis, ventricular hypertrophy, and cardiomyocyte apoptosis, and increase of vascular density and arterial density, as per histologic analysis of the treated hearts. Expression of cell proliferation markers (eg, Ki67, phosphorylated histone 3, and Aurora B kinase) was also significantly upregulated in the recipient cardiomyocytes from the CCND2 OE CM-treated than from the CCND2 WT CM-treated pigs. The cell proliferation rate and the hypoxia tolerance measured in cultured human induced pluripotent stem cell cardiomyocytes were significantly greater after treatment with exosomes isolated from the CCND2 OE CMs (CCND2 OE Exos) than from the CCND2 WT CMs (CCND2 WT Exos). As demonstrated by our study, CCND2 OE Exos can also promote the proliferation activity of postnatal rat and adult mouse cardiomyocytes. A bulk miRNA sequencing analysis of CCND2 OE Exos versus CCND2 WT Exos identified 206 and 91 miRNAs that were significantly upregulated and downregulated, respectively. Gene ontology enrichment analysis identified significant differences in the expression profiles of miRNAs from various functional categories and pathways, including miRNAs implicated in cell-cycle checkpoints (G2/M and G1/S transitions), or the mechanism of cytokinesis. Conclusions: We demonstrated that enhanced potency of CCND2 OE CMs promoted myocyte proliferation in both grafts and recipient tissue in a large mammal acute myocardial infarction model. These results suggest that CCND2 OE CMs transplantation may be a potential therapeutic strategy for the repair of infarcted hearts.